UNSPSC 51381512: Meclofenamic acid

This classification denotes a cyclooxygenase inhibitor and veterinary nonsteroidal anti inflammatory drug with the molecular formula C14H11Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48I5LU4ZWD, chemically known as 2-(2, 6-dichloro-3-methylphenyl)aminobenzoic acid but generally known as meclofenamic acid, which bears US NIH Compound Identifier 4037. European Medicines Agency schedules Meclofenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08678MIG.

UNSPSC 51381512 Meclofenamic acid is a Commodity code that in recent state and local procurement appears to cover a much broader range of pharmaceuticals and related health products than the code name alone suggests. The recent opportunities tagged under this code include naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs — indicating that state and local buyers are using the code to solicit pharmaceutical supply across multiple therapeutic categories and delivery models. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). These solicitations span different procurement approaches: competitive sealed bidding for specific, defined products; RFI market intelligence gathering to explore alternative contracting models; and formal RFP processes for framework agreements with multiple authorized wholesalers.

The code sees recent activity across Florida, Texas, and Minnesota, with interstate reach through cooperative purchasing vehicles. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with awards effective July 1, 2026. MMCAP requires vendors to certify cGMP and DSCSA compliance, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee, with evaluation weighted 75 percent on price competitiveness. Neither the Seminole County nor MMCAP solicitations specify explicit set-aside designations.